Clinical practice of treating platelet transfusion refractoriness based on platelet HLA gene bank matching.
- Author:
Yan LIU
1
;
Lili LIU
1
;
Jingru SHAO
1
;
Xiangmin NIE
1
;
Peicong ZHAI
2
Author Information
1. HLA laboratory, Blood Center of Shandong Province, Jinan 250014, China.
2. HLA laboratory, Blood Center of Shandong Province, Jinan 250014, China. *Corresponding author, E-mail: 1803911422@qq.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Platelet Transfusion/adverse effects*;
HLA Antigens/immunology*;
Male;
Middle Aged;
Female;
Adult;
Blood Platelets/immunology*;
Aged;
Genotype
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(7):644-648
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic efficacy of HLA-genotype matched platelet transfusion using a platelet donor database for severe platelet transfusion refractoriness (PTR) caused by HLA antigen-antibody incompatibility. Methods Using real-time quantitative PCR (qPCR) to identify he patient's HLA class I genotype, followed by searching the platelet donor database for matching donors, and selecting highly compatible donors for transfusion. Platelets with higher compatibility levels were prioritized for transfusion recommendations. Results Among the 19 patients studied, 7 patients identified donors with B2U or higher compatibility, 6 patients identified donors with BX or higher compatibility, and 6 patients did not find a suitable donor. The transfusion efficacy was evaluated by calculating the corrected count increment (CCI) 24 hours post-transfusion, and all transfusions were effective. Conclusion The optimal strategy to prevent and treat patients with severe platelet transfusion refractoriness is to ensure patients receive platelet transfusions that are matched to their HLA genes, and this approach significantly enhances transfusion efficacy.
